119 related articles for article (PubMed ID: 16365613)
1. Impact of medical comorbidity on the quality of schizophrenia pharmacotherapy in a national VA sample.
Chwastiak L; Rosenheck R; Leslie D
Med Care; 2006 Jan; 44(1):55-61. PubMed ID: 16365613
[TBL] [Abstract][Full Text] [Related]
2. Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Department of Veterans Affairs and the private sector.
Leslie DL; Rosenheck RA
J Ment Health Policy Econ; 2003 Sep; 6(3):113-21. PubMed ID: 14646004
[TBL] [Abstract][Full Text] [Related]
3. Use of pharmacy data to assess quality of pharmacotherapy for schizophrenia in a national health care system: individual and facility predictors.
Leslie DL; Rosenheck RA
Med Care; 2001 Sep; 39(9):923-33. PubMed ID: 11502950
[TBL] [Abstract][Full Text] [Related]
4. Off-label use of antipsychotic medications in the department of Veterans Affairs health care system.
Leslie DL; Mohamed S; Rosenheck RA
Psychiatr Serv; 2009 Sep; 60(9):1175-81. PubMed ID: 19723731
[TBL] [Abstract][Full Text] [Related]
5. The effect of institutional fiscal stress on the use of atypical antipsychotic medications in the treatment of schizophrenia.
Leslie DL; Rosenheck R
J Nerv Ment Dis; 2001 Jun; 189(6):377-83. PubMed ID: 11434638
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: diagnostic- and symptom-guided drug selection.
Mohamed S; Rosenheck RA
J Clin Psychiatry; 2008 Jun; 69(6):959-65. PubMed ID: 18588361
[TBL] [Abstract][Full Text] [Related]
7. Patient- and facility-level factors associated with diffusion of a new antipsychotic in the VA health system.
Valenstein M; McCarthy JF; Ignacio RV; Dalack GW; Stavenger T; Blow FC
Psychiatr Serv; 2006 Jan; 57(1):70-6. PubMed ID: 16399965
[TBL] [Abstract][Full Text] [Related]
8. From conventional to atypical antipsychotics and back: dynamic processes in the diffusion of new medications.
Leslie DL; Rosenheck RA
Am J Psychiatry; 2002 Sep; 159(9):1534-40. PubMed ID: 12202274
[TBL] [Abstract][Full Text] [Related]
9. Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.
Kreyenbuhl JA; Valenstein M; McCarthy JF; Ganoczy D; Blow FC
Psychiatr Serv; 2007 Apr; 58(4):489-95. PubMed ID: 17412850
[TBL] [Abstract][Full Text] [Related]
10. Adherence of schizophrenia pharmacotherapy to published treatment recommendations: patient, facility, and provider predictors.
Leslie DL; Rosenheck RA
Schizophr Bull; 2004; 30(3):649-58. PubMed ID: 15631257
[TBL] [Abstract][Full Text] [Related]
11. Administrative prescription review procedures and use of atypical antipsychotic medications in the Department of Veterans Affairs.
Rosenheck R; Leslie D
Ment Health Serv Res; 2003 Sep; 5(3):149-53. PubMed ID: 15224448
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic use in the treatment of outpatients with schizophrenia in the VA from fiscal years 1999 to 2006.
Sernyak MJ; Rosenheck RA
Psychiatr Serv; 2008 May; 59(5):567-9. PubMed ID: 18451019
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
[TBL] [Abstract][Full Text] [Related]
14. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs.
Mohamed S; Leslie DL; Rosenheck RA
J Clin Psychiatry; 2009 Jun; 70(6):906-12. PubMed ID: 19422760
[TBL] [Abstract][Full Text] [Related]
15. Assertive community treatment in veterans affairs settings: impact on adherence to antipsychotic medication.
Valenstein M; McCarthy JF; Ganoczy D; Bowersox NW; Dixon LB; Miller R; Visnic S; Slade EP
Psychiatr Serv; 2013 May; 64(5):445-51, 451.e1. PubMed ID: 23412131
[TBL] [Abstract][Full Text] [Related]
16. Variations in prescribing practices for novel antipsychotic medications among Veterans Affairs hospitals.
Owen RR; Feng W; Thrush CR; Hudson TJ; Austen MA
Psychiatr Serv; 2001 Nov; 52(11):1523-5. PubMed ID: 11684751
[TBL] [Abstract][Full Text] [Related]
17. Polypharmacy with antipsychotic drugs in patients with schizophrenia: trends in multiple health care systems.
Sun F; Stock EM; Copeland LA; Zeber JE; Ahmedani BK; Morissette SB
Am J Health Syst Pharm; 2014 May; 71(9):728-38. PubMed ID: 24733136
[TBL] [Abstract][Full Text] [Related]
18. Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.
Ren XS; Kazis LE; Lee AF; Huang YH; Hamed A; Cunningham F; Herz L; Miller DR
Schizophr Res; 2005 Sep; 77(2-3):167-77. PubMed ID: 15894460
[TBL] [Abstract][Full Text] [Related]
19. Gender differences in antipsychotics prescribed to veterans with serious mental illness.
Schwartz E; Charlotte M; Slade E; Medoff D; Li L; Dixon L; Kilbourne A; Kreyenbuhl J
Gen Hosp Psychiatry; 2015; 37(4):347-51. PubMed ID: 25936673
[TBL] [Abstract][Full Text] [Related]
20. PTSD and substance use disorder among veterans: characteristics, service utilization and pharmacotherapy.
Bowe A; Rosenheck R
J Dual Diagn; 2015; 11(1):22-32. PubMed ID: 25513763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
